On Wednesday morning, both A-Shares and Hong Kong shares were adjusted, of which the adjustment range of A-share market was small, and the "real estate chain" stocks rose sharply. Overall, individual stocks rose more and fell less, with more than 3100 stocks rising in the two cities.
In the Hong Kong stock market, the Hang Seng technology index once fell more than 4% in midday trading, and most Hong Kong stocks fell. However, some stocks rose sharply against the trend, and Hong Kong stocks developed pharmaceutical-b, which once rose more than 200%.
This morning, the topic of "fund" rushed to the microblog hot search list again.
A-Shares slightly adjusted
"real estate chain" stocks rose sharply
The A-share market adjusted slightly this morning. The Shanghai Composite Index and Shenzhen composite index fell by less than 1% most of the morning.
In terms of industry sectors, the semiconductor sector led the decline, with a decline of more than 3% 3Peak Incorporated(688536) fell by more than 10%, with Starpower Semiconductor Ltd(603290) , Changguang Huaxin, Yangzhou Yangjie Electronic Technology Co.Ltd(300373) , Macmic Science & Technology Co.Ltd(688711) leading the decline.
The decline in the coal sector was more obvious Shanxi Coking Coal Energy Group Co.Ltd(000983) , Shanxi Lu'An Environmental Energydev.Co.Ltd(601699) , Jizhong Energy Resources Co.Ltd(000937) , Shaanxi Coal Industry Company Limited(601225) .
Electrical equipment, water, mineral products and other sectors led the decline.
Some stocks in the tourism sector rose sharply, Tempus Global Business Service Group Holding Ltd(300178) "20cm" limit, Jiangsu Tianmu Lake Tourism Co.Ltd(603136) limit, Anhui Jiuhuashan Tourism Development Co.Ltd(603199) , Changbai Mountain Tourism Co.Ltd(603099) .
The education sector rose sharply, and the education index rose nearly 6%. In terms of individual stocks in the sector, Qtone Education Group(Guangdong) Co.Ltd(300359) "20cm" limit, Jiangsu Chuanzhiboke Education Technology Co.Ltd(003032) , Xueda (Xiamen) Education Technology Group Co.Ltd(000526) , Shanghai Xinnanyang Only Education & Technology Co.Ltd(600661) limit, Sansheng Intellectual Education Technology Co.Ltd(300282) limit rose by more than 8%, and Beijing Kaiwen Education Technology Co.Ltd(002659) , Kaiyuan Education Technology Group Co.Ltd(300338) limit rose by more than 7%.
Stocks in the "real estate chain" sector rose sharply. Many stocks in the real estate sector rose sharply, and about 10 stocks, including Nanjing Chixia Development Co.Ltd(600533) , China Wuyi Co.Ltd(000797) , Cccg Real Estate Corporation Limited(000736) , Shenzhen New Nanshan Holding (Group) Co.Ltd(002314) , Shanghai Huitong Energy Co.Ltd(600605) , China Fortune Land Development Co.Ltd(600340) , Shahe Industrial Co.Ltd(000014) , Langold Real Estate Co.Ltd(002305) , impacted the intraday limit. Among them, Langold Real Estate Co.Ltd(002305) , China Wuyi Co.Ltd(000797) and Cccg Real Estate Corporation Limited(000736) increased the limit for 4 consecutive trading days and Cccg Real Estate Corporation Limited(000736) for 7 consecutive trading days.
The household goods sector bucked the trend and rose sharply A-Zenith Home Furnishings Co.Ltd(603389) limit, Zbom Home Collection Co.Ltd(603801) , Suofeiya Home Collection Co.Ltd(002572) , etc. were among the top gainers.
Construction sector stocks rose, Shenzhen Strongteam Decoration Engineering Co.Ltd(002989) limit, Guangdong No.2 Hydropower Engineering Company Ltd(002060) , Zhengping Road & Bridge Construction Co.Ltd(603843) , Shenzhen Minkave Technology Co.Ltd(300506) .
In terms of concept stocks, the concept of chicken rose sharply, Shandong Minhe Animal Husbandry Co.Ltd(002234) limit, Shandong Yisheng Livestock & Poultry Breeding Co.Ltd(002458) , Springsnow Food Group Co.Ltd(605567) etc.
Covid-19 drug concept rose sharply Xiangxue Pharmaceutical Co.Ltd(300147) , Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) , Dali Pharmaceutical Co.Ltd(603963) , Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) , Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) and other stocks rose by the limit.
Huaan Securities Co.Ltd(600909) in the second quarter strategy report, it is believed that the valuation quantile of the main indexes has decreased significantly, which is in the low central position, and has good cost performance in the medium and long term. Among them, by the end of the first quarter, the valuation of Shanghai stock index was only 12.5x, which was at the 33% valuation quantile level since 2010. The valuation was lower than that after the continuous circuit breaker in the market at the beginning of 2016 and slightly higher than that after the epidemic fell in March 2020; Gem refers to the current valuation of only 52X, which is at the quantile level of 45% valuation since 2010, which is equivalent to that after falling due to the epidemic in March 2020. From a medium and long-term perspective, the current valuation level has a good margin of safety and good cost performance.
Huaan Securities Co.Ltd(600909) believes that the valuation level of the industry has decreased significantly, and the valuation of some growth industries and pharmaceutical industries is significantly low. For example, the current valuation of the electronics industry is only 25.5x, which is at the valuation quantile level of less than 3% since 2010, which is lower than that before the start of the growth market in 2013, which is equivalent to the valuation when the market was the most pessimistic at the end of 2018; At present, the pharmaceutical industry is estimated to be only 31.1x, at the valuation quantile level of only 10% since 2010, which is only a little higher than that before the start of the market in early 2012 and early 2019. The valuations of some industries are basically absolutely undervalued.
overall adjustment of Hong Kong stocks
Hong Kong stock development pharmaceutical soared by more than 200%
In the morning, the Hong Kong stock market fell into adjustment, the Hang Seng Index approached the 22000 mark, and the decline in most of the morning was between 1% and 2%.
Hang Seng technology index fell even more, with an intraday decline of more than 4%.
Among the constituent stocks of Hang Seng technology index, Shunyu optical technology, Byd Company Limited(002594) electronics, Kingdee International, Huahong semiconductor, ctrip-s, Jinshan software, etc. led the decline.
Hong Kong stock development pharmaceutical-b soared, with an intraday increase of more than 200%.
Kaifa-b announced in the morning that the board of directors of the company announced the key data results of phase III clinical trial of prochloramide in the treatment of mild and moderate non hospitalized covid-19 patients (nct04870606) (the "clinical trial"). The clinical trial is a double-blind, placebo-controlled, randomized (1:1), global multi center registered clinical trial. Since April 24, 2021, the first subject in the world was enrolled, 733 subjects worldwide were enrolled on December 24, 2021 (727 from the United States and the rest from other countries), and the last subject's last visit was completed on February 3, 2022. The subjects were given oral prochloramide 200mg once a day + standard treatment ("prochloramide group") or placebo + standard treatment ("control group"), and the treatment period was 14 days. The subjects enrolled in the clinical trial have covid-19 symptoms for no more than five days for the first time, regardless of whether there are risk factors, and the subjects who have been vaccinated with covid-19 vaccine are not excluded. The end point of the clinical trial was the percentage of subjects who had not been hospitalized for ≥ 24 hours or died due to peripheral oxygen saturation (SpO2) ≤ 93% for ≥ 24 hours by day 28; The incidence of hospitalization or oxygen inhalation ≥ 24 hours or death due to peripheral blood oxygen saturation ≤ 93% within 28 days; Changes in viral load and safety assessment from baseline to day 28.
Pioneer pharmaceutical said that the main data show that prochloramide can effectively reduce hospitalization / mortality, especially for subjects taking medicine for more than 7 days and middle and high-age subjects with high risk factors. At the same time, prochloramide can significantly and continuously reduce covid-19 virus load and improve covid-19 related symptoms.
In terms of safety data, the announcement said that the results of the clinical trial showed that the overall tolerability of prochloramide in the treatment of mild and moderate covid-19 subjects was good, safe and controllable. During the whole trial, the incidence of adverse events was 7.9% in the control group and 9.6% in the prochloramide group, most of which were mild. The most common adverse event was vertigo (1.1% in the control group and prochloramide group), and the incidence of any other adverse events was less than 1%. There were no serious adverse events in the study.
